Checkpoint Therapeutics Merges with Sun Pharma for $416M

Checkpoint Therapeutics ( (CKPT) ) just unveiled an update.

On March 9, 2025, Checkpoint Therapeutics entered into a Merger Agreement with Sun Pharmaceutical Industries, where Sun Pharma will acquire Checkpoint. The transaction, valued at up to $416 million, includes an upfront cash payment of $4.10 per share and a contingent value right of up to $0.70 per share upon achieving specific milestones. This merger is expected to bolster Sun Pharma’s onco-dermatology portfolio and accelerate global access to Checkpoint’s FDA-approved treatment, UNLOXCYT™. The transaction is subject to customary closing conditions and is anticipated to complete in the second quarter of 2025.

More about Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on developing novel treatments for patients with solid tumor cancers. The company has received FDA approval for UNLOXCYT™ (cosibelimab-ipdl) for treating adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation. Checkpoint is also evaluating olafertinib, a third-generation EGFR inhibitor, for EGFR mutation-positive non-small cell lung cancer.

YTD Price Performance: -24.92%

Average Trading Volume: 1,325,432

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $120.6M

Find detailed analytics on CKPT stock on TipRanks’ Stock Analysis page.